Cargando…
Phenotypic Fingerprinting of Small Molecule Cell Cycle Kinase Inhibitors for Drug Discovery
Phenotypic drug discovery, primarily abandoned in the 1980’s in favor of targeted approaches to drug development, is once again demonstrating its value when used in conjunction with new technologies. Phenotypic discovery has been brought back to the fore mainly due to recent advances in the field of...
Autores principales: | Low, Jonathan, Chakravartty, Arunava, Blosser, Wayne, Dowless, Michele, Chalfant, Christopher, Bragger, Patty, Stancato, Louis |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793401/ https://www.ncbi.nlm.nih.gov/pubmed/20161832 http://dx.doi.org/10.2174/1875397300903010013 |
Ejemplares similares
-
Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy
por: Lowery, Caitlin D., et al.
Publicado: (2019) -
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
por: Vakana, Eliza, et al.
Publicado: (2016) -
Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F
por: Ma, L, et al.
Publicado: (2013) -
A Method to Assess Target Gene Involvement in Angiogenesis In Vitro and In Vivo Using Lentiviral Vectors Expressing shRNA
por: Blosser, Wayne, et al.
Publicado: (2014) -
Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies
por: Peng, Sheng-Bin, et al.
Publicado: (2016)